208 related articles for article (PubMed ID: 24094602)
1. Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.
Papageorgiou C; Vandreden P; Marret E; Bonnet F; Robert F; Spyropoulos A; Galea V; Elalamy I; Hatmi M; Gerotziafas GT
Thromb Res; 2013 Nov; 132(5):584-91. PubMed ID: 24094602
[TBL] [Abstract][Full Text] [Related]
2. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
3. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Syrigos K; Grapsa D; Sangare R; Evmorfiadis I; Larsen AK; Van Dreden P; Boura P; Charpidou A; Kotteas E; Sergentanis TN; Elalamy I; Falanga A; Gerotziafas GT
Oncologist; 2018 Nov; 23(11):1372-1381. PubMed ID: 30104289
[TBL] [Abstract][Full Text] [Related]
4. The study of the thrombin generation mechanism and the effect of low molecular weight heparin as thromboprophylaxis in patients undergoing total knee and hip replacement.
Gionis MN; Ioannou CV; Katsamouris AN; Katonis P; Balalis K; Sfyridaki K; Elalamy I; Gerotziafas GT
Thromb Res; 2013; 132(6):685-91. PubMed ID: 24182549
[TBL] [Abstract][Full Text] [Related]
5. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.
Chaari M; Ayadi I; Rousseau A; Lefkou E; Van Dreden P; Sidibe F; Ketatni H; Galea V; Khaterchi A; Bouzguenda R; Frikha M; Ghorbal L; Daoud J; Kallel C; Quinn M; Gligorov J; Lotz JP; Hatmi M; Elalamy I; Gerotziafas GT
BMC Cancer; 2014 Dec; 14():991. PubMed ID: 25535397
[TBL] [Abstract][Full Text] [Related]
6. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Brophy DF; Martin EJ; Gehr TW; Carr ME
Am J Kidney Dis; 2004 Aug; 44(2):270-7. PubMed ID: 15264185
[TBL] [Abstract][Full Text] [Related]
7. The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
Sassi M; Chakroun T; Mbemba E; Van Dreden P; Elalamy I; Larsen AK; Gerotziafas GT
Clin Appl Thromb Hemost; 2017 Mar; 23(2):155-163. PubMed ID: 27609342
[TBL] [Abstract][Full Text] [Related]
8. The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
Gerotziafas GT; Van Dreden P; Chaari M; Galea V; Khaterchi A; Lionnet F; Stankovic-Stojanovic K; Blanc-Brude O; Woodhams B; Maier-Redelsperger M; Girot R; Hatmi M; Elalamy I
Thromb Haemost; 2012 Jun; 107(6):1044-52. PubMed ID: 22535498
[TBL] [Abstract][Full Text] [Related]
9. Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
Oswald E; Velik-Salchner C; Innerhofer P; Tauber H; Auckenthaler T; Ulmer H; Streif W
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):136-44. PubMed ID: 25396759
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of enoxaparin oligosaccharides, antifactor-Xa and thrombin generation in patients undergoing haemodialysis.
Batt TJ; Lincz LF; Prasad R; Patel RP; Shastri M; Lioufas N; Smith AG; Jose MD
Blood Coagul Fibrinolysis; 2020 Mar; 31(2):152-159. PubMed ID: 31990754
[TBL] [Abstract][Full Text] [Related]
11. Procoagulant activity in gynaecological cancer patients; the effect of surgery and chemotherapy.
Abu Saadeh F; Langhe R; Galvin DM; O Toole SA; O'Donnell DM; Gleeson N; Norris LA
Thromb Res; 2016 Mar; 139():135-41. PubMed ID: 26916311
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
[TBL] [Abstract][Full Text] [Related]
13. The Levels of Tissue Factor Pathway Inhibitor in Sepsis Patients Receiving Prophylactic Enoxaparin.
Al Otair HA; Abdel Gader AG; Khurshid SM; Alzeer AH; Al Momen AK; Al Shaikh M; Al Gahtani F; Al Aseri ZA; Abdelrazik HA
Turk J Haematol; 2016 Jun; 33(2):112-8. PubMed ID: 26377606
[TBL] [Abstract][Full Text] [Related]
14. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study.
Steib A; Degirmenci SE; Junke E; Asehnoune K; Figier M; Pericard C; Rohr S; Letessier E; Brunaud L; Vix M; Zobairi F; Grunebaum L; Toti F
Surg Obes Relat Dis; 2016; 12(3):613-621. PubMed ID: 26686309
[TBL] [Abstract][Full Text] [Related]
15. Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events.
Campello E; Zabeo E; Radu CM; Spiezia L; Gavasso S; Fadin M; Woodhams B; Vettor R; Simioni P
Thromb Haemost; 2015 Jan; 113(1):85-96. PubMed ID: 25318550
[TBL] [Abstract][Full Text] [Related]
16. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
17. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Perzborn E; Heitmeier S; Buetehorn U; Laux V
J Thromb Haemost; 2014 Jul; 12(7):1054-65. PubMed ID: 24766850
[TBL] [Abstract][Full Text] [Related]
18. Heparin resistance and coagulation activation rebound effect after anticoagulant withdrawal: beneficiary effect of adjuvant antiplatelet therapy.
Gionis MN; Ioannou CV; Kontopodis N; Balalis K; Elalamy I; Gerotziafas GT
Int Angiol; 2016 Apr; 35(2):170-7. PubMed ID: 25765915
[TBL] [Abstract][Full Text] [Related]
19. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation.
Ben-Hadj-Khalifa S; Hézard N; Almawi WY; Remy MG; Florent B; Mahjoub T; Nguyen P
Blood Coagul Fibrinolysis; 2011 Jul; 22(5):369-73. PubMed ID: 21577096
[TBL] [Abstract][Full Text] [Related]
20. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations.
Klein SM; Slaughter TF; Vail PT; Ginsberg B; El-Moalem HE; Alexander R; D'Ercole F; Greengrass RA; Perumal TT; Welsby I; Gan TJ
Anesth Analg; 2000 Nov; 91(5):1091-5. PubMed ID: 11049889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
